GIM
APGE icon

Glenmede Investment Management’s Apogee Therapeutics APGE Stock Holding History

Glenmede Investment Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$323K Sell
8,127
-730
-8% -$27.9K ﹤0.01% 1095
2025
Q2 		$385K Buy
+8,857
New +$337K ﹤0.01% 1020

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Glenmede Investment Management's APGE Position: Q3 2025 in Review

Glenmede Investment Management reduced its Apogee Therapeutics (APGE) stake by 8.2% in Q3 2025, selling an estimated $27.9K and leaving 8,127 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

Glenmede Investment Management first reported a position in APGE in Q2 2025 and has held it in 2 quarters since. The position peaked at $385K in Q2 2025. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • Glenmede Investment Management held 8,127 shares of Apogee Therapeutics worth $323K as of Q3 2025.
  • Glenmede Investment Management sold 730 Apogee Therapeutics shares in Q3 2025, an estimated $27.9K.
  • Apogee Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1095 holding.
  • Glenmede Investment Management first reported a position in Apogee Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Apogee Therapeutics position peaked at $385K in Q2 2025.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.